Abstract RF7-03: Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: F. Bidard, E. L. Mayer, Y. Park, W. Janni, C. Ma, M. Cristofanilli, G. Bianchini, K. Kalinsky, H. Iwata, S. Chia, A. Brufsky, P. Fasching, Z. Nowecki, J. Pascual, E. Gal-Yam, W. Chung, S. Im, A. Zambelli, F. Dalenc, M. Oliveira, S. Fox, M. Selvi Miralles, C. Morrow, C. Huang Bartlett, N. C. Turner
Institutions: Institut Curie, Dana-Farber Cancer Institute, Samsung Medical Center, Sungkyunkwan University, University Hospital Ulm, Washington University in St. Louis, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, IRCCS Ospedale San Raffaele, Winship Cancer Institute, Nagoya City University, BC Cancer Agency, Magee-Womens Hospital, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Sheba Medical Center, National Cheng Kung University Hospital, National Cheng Kung University, Seoul National University, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, Vall d'Hebron Hospital Universitari, AstraZeneca (United Kingdom), AstraZeneca (United States), Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129619433